

# Training Courses

Thursday, October 4

## HPV Infection in Clinical Practice: From Screening to Prevention

Prince Pierre auditorium

### **TC 1** HPV Infection and Associated Disease: the Essentials for Clinical Practice

*Chair: A. Ferenczy (Canada)*

#### **PART 1**

- TC1-1** • The burden of HPV related disease
- TC1-2** • Natural history and carcinogenesis
- TC1-3** • Immunology of HPV Infection
- TC1-4** • Methods of HPV detection and clinical value
- TC1-5** • Cytology of HPV associated disease
- TC1-6** • Histology of CIN

**8:15 - 10:30**

E. Franco (Canada)  
S. De Sanjosé (Spain)  
J. Dillner (Sweden)  
M. Stoler (US)  
A. Ferenczy (Canada)  
K. Syrjänen (Finland)

#### **Coffee Break**

**10:30 - 11:00**

#### **PART 2**

- TC1-7** • Colposcopy of CIN / VAIN / VIN and cancer
- TC1-8** • Management options for abnormal PAP
- TC1-9** • Screening strategies in developed and developing countries

**11:00 - 12:15**

A. Singer (UK)  
T. Cox (US)  
  
J. Cuzick (UK)

### **TC 2** HPV Prophylactic Vaccines in Clinical Practice

*Chair: I. Frazer (Australia)*

#### **PART 1**

- TC2-1** • Understanding mechanisms of action
- TC2-2** • Immunogenicity and safety
- HPV vaccines efficacy: lessons from clinical trials
- TC2-3** - Quadrivalent
- TC2-4** - Bivalent
- TC2-5** • Prophylactic vs. therapeutic effects

**14:00 - 15:30**

J. Schiller (US)  
S. Garland (Australia)  
  
K. Ault (US)  
D. Harper (US)  
P. Castle (US)

#### **Coffee Break**

**15:30 - 16:00**

#### **PART 2**

- TC2-6** • Target population
- TC2-7** • Public health issues
- TC2-8** • Unresolved issues
- TC2-9** • Practical issues:  
Integrating HPV vaccination into clinical practice

**16:00 - 17:00**

J. Paavonen (Finland)  
R. Sankaranarayanan (France)  
I. Frazer (Australia)  
  
T. Wright (US)

# Plenary Sessions

## PLENARY SESSION I Global Strategies for Prophylactic HPV Vaccination

Friday, October 5  
Salle des Princes auditorium

Opening Lecture:		<b>8:00 – 8:20</b>
	• Present Status and Challenges of HPV Vaccines	I. Frazer (Australia)
1. Clinical Issues: the State of the Art		<b>8:20 – 9:00</b>
Chair: D. Harper (US), J. Paavonen (Finland)		
PS 1-1-1	• Updating clinical issues	J. Schiller (US)
PS 1-1-2	• Post market surveillance	J. Paavonen (Finland)
PS 1-1-3	• The patient perspectives	D. Harper (US)
2. Research Perspectives		<b>9:00 – 9:30</b>
Chair: J. Schiller (US) – I. Frazer (Australia)		
PS 1-2-1	• Adjuvants	F. Zepp (Germany)
PS 1-2-2	• What new proofs are needed to foster universal implementation of HPV vaccines	E. Franco (Canada)
PS 1-2-3	• Multivalent vaccines	L. Villa (Brazil)
3. Public Health Dimension - Policy and Societal Issues		<b>9:30 – 10:30</b>
Chair: K. Irwin (Switzerland) – H. Lawson (US)		
PS 1-3-1	• Developed countries	H. Lawson (US)
PS 1-3-2	• Developing world.	K. Irwin (Switzerland)
PS 1-3-3	• Advocacy and vaccination: psychosocial and ethical issues	GD Zimet (US)
PS 1-3-4	• Integrating HPV vaccines with other preventive measures	M. Steben (Canada)

**Coffee Break** **10:30 – 11:00**

## PLENARY SESSION II New Screening Approaches and Management Strategies in the HPV Vaccine Era

Saturday, October 6  
Prince Pierre auditorium

		<b>8:00 – 9:00</b>
Chair: J. Cuzick (UK) - T. Wright (US)		
PS 2-1	• HPV testing as a more logical screening approach following vaccination	E. Franco (Canada)
PS 2-2	• HPV testing as primary screening approach: the findings from clinical studies	J. Cuzick (UK)
PS 2-3	• Implementing low technology screening strategies in developing countries	T. Wright (US)
PS 2-4	• Updating current management strategies: the role of genotyping and molecular markers	P. Castle (US)

## PLENARY SESSION III

Saturday, October 6

**9:00 – 10:30**

### Guidelines on HPV Prophylactic Vaccines – How to apply in Clinical Practice

General coordination: J. Monsonego (France), A. Singer (UK)  
Chair: C. Wheeler (US), S. Franceschi (France)

#### Topics:

- Age for vaccination  
D. Harper (US), J. Paavonen (Finland)
- Is viral status needed before vaccination?  
T. Wright (US), X. Bosch (Spain)
- Screening approach for vaccinated population  
E. Franco (Canada), J. Cuzick (UK)
- Monitoring of vaccinated women  
M. Stanley (UK), L. Villa (Brazil)

#### Group of reviewers:

K. Ault (US), F. Breitburd (France), C. Clavel (France), L. Denny (RSA), J. Dillner (Sweden), B. Duval (Canada), Elbasha (US), A. Ferenczy (Canada), J.M. Foidard (Belgium), I. Frazer (Australia), G. Garnett (UK), S. Goldie (US), A. Hildesheim (US), P. Hillemans (Germany), E. Joura (Austria), W. Kinney (US), H. Lawson (US), Lehtinen (Finland), C. Meijer (Netherlands), A. Moscicki (US), N. Munoz (France), D. Nardelli-Haefliger (Switzerland), S. Pagliusi (Switzerland), J. Patnick (UK), K.U. Petry (Germany), W. Prendiville (Ireland), M. Quinn (Australia), G. Ronco (Italy), P. Sasieni (UK), M. Schiffmann (US), J. Schiller (US), A. Schneider (Germany), T. Schwarz (Germany), J. Sherris (US), J. Smith (US), H. Strickler, S. Syrjänen (Finland), J. Wardle (UK).

**Coffee Break**

**10:30 – 11:00**

## Infection à Papillomavirus

### Nouvelles stratégies de prévention du cancer du col utérin

*Dans le domaine de l'infection génitale à HPV et des lésions associées, la connaissance et les pratiques vont connaître des évolutions significatives.*

*La perspective d'un dépistage mieux organisé, basé sur le risque, la mise à disposition de marqueurs de risque et de détection plus fiables et plus spécifiques, des outils encore plus performants d'imagerie et de traitements, vont bouleverser les pratiques traditionnelles.*

*La vaccination anti-HPV qui a pour objectif de prévenir les pré-cancers et cancers du bas appareil génital est une innovation majeure. Pour la première fois, il est possible de se protéger contre une tumeur solide viro induite. C'est aussi une formidable victoire pour la santé des femmes depuis l'extraordinaire contribution du frottis de dépistage il y a une cinquantaine d'années, à faire reculer la maladie. Elle inaugure une ère nouvelle dans la prévention de la maladie.*

#### PERSONNES CONCERNÉES

Le congrès PROGIN s'adresse à tous les professionnels impliqués :  
- aux gynécologues, cytopathologistes, biologistes, internes et étudiants.

- aux chefs de projet recherche et développement et chargés d'étude de l'industrie.

Au-delà de son aspect pédagogique et stratégique, ce congrès sera l'occasion de rencontrer dans un cadre agréable les différents acteurs, experts et leaders impliqués dans ce domaine, où il sera possible d'échanger et de débattre librement avec les experts qui animent la manifestation.

#### OBJECTIFS DU CONGRÈS

Le Congrès National PROGIN 2007 s'est fixé comme objectifs de :

- Faire le point sur les récents développements dans le contrôle du cancer du col et des maladies associées aux papillomavirus. L'accent sera mis sur les nouvelles stratégies de prévention à l'ère vaccinale.
- Faire le point sur les récents développements sur l'infection à HPV et la prévention du cancer du col.
- Intégrer l'utilisation du vaccin HPV prophylactique à la pratique clinique
- Maîtriser l'impact qu'auront les vaccins sur le contrôle de la maladie
- Comparer les expériences dans ce domaine
- Intégrer les recommandations existantes à la pratique clinique

*Dans cet environnement en pleine évolution et encore entaché de certaines incertitudes, décrypter les nouveaux enjeux, anticiper les évolutions à court et moyen terme, définir des stratégies cohérentes de prises en charge et rationaliser les pratiques sont des impératifs.*

*En 2007, nous avons souhaité rassembler au sein de la conférence internationale d'EUROGIN, tous ceux qui souhaitent parfaire leurs connaissances, se former aux bonnes pratiques cliniques, s'informer des récents développements et anticiper les pratiques de demain.*

*J'invite tous ceux qui sont impliqués dans le dépistage et la prévention du cancer du col à s'associer à cet événement d'excellence dans un environnement scientifique international exceptionnel.*

J. MONSONEGO

Directeur du Programme Scientifique

En marge de la prévention vaccinale, les participants devront :

- Acquérir les connaissances nécessaires de la biologie, l'épidémiologie et l'immunologie de l'infection à HPV
- Comprendre les bases du diagnostic morphologique et biologique de l'infection à HPV
- S'initier et se perfectionner à la pratique de la colposcopie
- Faire l'apprentissage des prises de décision en pathologie cervicale
- Maîtriser et appliquer les méthodes thérapeutiques et leurs indications
- Conduire une consultation de pathologie vulvaire à papillomavirus

#### A LA FIN DU CONGRÈS LES PARTICIPANTS DOIVENT ÊTRE EN MESURE

- de proposer la vaccination HPV selon l'âge et les recommandations,
- de maîtriser les indications et la pratique du test HPV en routine,
- de mener un examen colposcopique et d'évaluer les lésions
- de prendre des décisions en fonction des situations cliniques et de maîtriser les indications et les méthodes thérapeutiques,
- de répondre aux questions le plus souvent posées.

#### FMC

Une attestation sera délivrée pour justifier de la participation et de l'évaluation.

Numéro d'agrément d'EUROGIN à la FMC : 117 524 04 975.

# Infection à papillomavirus Nouvelles stratégies de prévention du cancer du col utérin

Vendredi 5 Octobre  
Bosio

Samedi 6 Octobre  
Bosio

**PR 1** Les professionnels face à la vaccination prophylactique contre les HPV **8:15 - 10:30**

*Présidents : J. Monsonogo, P. Coursaget*

- PR 1-1** • Etendue de l'infection à HPV : les nouveautés A. Ferenczy(Canada)
- PR 1-2** • Résultats des essais cliniques, les points sur l'efficacité vaccinale :  
- Gardasil® B. Soubeyrand  
- Cervarix® V. Abitbol
- PR 1-3** • Etat des recherches en cours et perspectives de développement P. Coursaget
- PR 1-4** • Nouvelles stratégies de prévention du cancer du col :  
incorporer la vaccination en pratique J. Monsonogo
- PR 1-5** • Les leçons des modélisations :  
- Condylomes acuminés C. Cohet  
- Cancer du col M.P. Allicar
- PR 1-6** • Les questions non encore résolues et perspectives P. Mathevet

**PAUSE** **10:30 - 11:00**

**CONGRÈS EUROGIN** **11:00 - 12:30**

**PR 2** Le point de vue des institutions françaises et la vaccination HPV **14:00 - 16:00**

*Présidents : C. Bismuth, J. Vigiuer*

- PR 2-1** • Institut National du Cancer (INCa) :  
Etat des lieux de la lutte contre le cancer en France S. Bremard
- PR 2-2** • Institut de Veille Sanitaire (InVS) :  
Evaluation du dépistage du cancer du col en France :  
le point en 2007 N. Duport
- PR 2-3** • Comité Technique des Vaccins (CTV) :  
Les recommandations françaises sur la vaccination HPV F. Denis
- PR 2-4** • Fédération Nationale des Centres de Lutte contre le Cancer  
– EPIDAURE : "L'information des pré-ados et des ados sur  
l'infection à HPV et ses conséquences H. Sancho-Garnier
- PR 2-5** • L'Assurance Maladie C. Bismuth
- PR 2-6** • Le comité national d'éthique D. Sicard

**PAUSE** **16:00 - 16:30**

**CONGRÈS EUROGIN** **16:30 - 19:15**

**SYMPOSIUM** CodePharma **18:00 - 19:00**

**PR 3** Questions sociétales et éthiques face à la vaccination à HPV **8:15 - 10:00**

*Présidents : Weil-Olivier, H. Sancho-Garnier*

- PR 3-1** • Témoignages de femmes :  
l'action de l'association 1000 femmes pour 1000 vies D. Castaigne
- PR 3-2** • Les questions le plus souvent posées sur la vaccination à HPV P. Faucher
- PR 3-3** • Programme d'éducation des patients et supports de communication E. Franco
- PR 3-4** • Apport des enquêtes nationales et internationales M. Steben (Canada)
- PR 3-5** • Acceptabilité des vaccins J. Gaudelus
- PR 3-6** • Attitudes des professionnels et des femmes face à la vaccination C. Weill-Olivier
- PR 3-7** • La relation médecin-patient face à l'HPV M. Steben (Canada)

**PR 4** Nouvelles technologies de diagnostic et de dépistage **10:00 - 11:15**

*Présidents : C. Clavel, P. Judlin*

- PR 4-1** • Distribution des HPV dans les cancers du col :  
une expérience française D. Riethmuller
- PR 4-2** • Le point sur l'apport du test HPV dans le dépistage,  
la prise en charge et le suivi M. Arbyn (Belgique)
- PR 4-3** • Où en est-on sur l'apport du test HPV dans  
le dépistage primaire en France C. Clavel
- PR 4-5** • Le test HPV dans le suivi J.L. Mergui

**PAUSE** **11:15 - 11:30**

**CONGRÈS EUROGIN** **11:30 - 14:00**

**PR 5** La pathologie HPV à l'ère vaccinale **14:00 - 17:00**

*Présidents : J.C. Boulanger, J.L. Mergui, M. Roy (Canada)*

- PR 5-1** • Epidémiologie des lésions génitales à HPV C. Mougin
- PR 5-2** • Diagnostic histologique : contrôle de qualité S. Labbé
- PR 5-3** • Condylomes acuminés : prévention, diagnostic et traitement M. Roy (Canada)
- PR 5-4** • Les CIN : prévention, colposcopie et traitement J.C. Boulanger
- PR 5-5** • Nouvelles données sur l'adénocarcinome X. Bosch (Espagne)
- PR 5-6** • Cancer du col et conservation de la fertilité D. Castaigne
- PR 5-7** • La pathologie HPV chez le séropositif pour le VIH I. Heard
- PR 5-8** • Grossesse et infection à HPV J. Gondry
- PR 5-9** • Les VaIN : diagnostic et traitement J.L. Leroy
- PR 5-10** • Les VuIN : diagnostic et traitement M. Roy (Canada)
- PR 5-11** • Apport de la vaccination thérapeutique J.P. Bory



# First Patient Education Conference on Cervical Cancer Prevention

## Sharing Experience and Action

Thursday, October 4

Thursday, October 4

### SESSION 1

Camille Blanc auditorium

#### 1.1 The Current Situation **8:30 – 9:20**

Chair: T. Cox (US) – C. Weil-Olivier (France)

- Testimonial: Christine Baze (US) 8:30 - 8:40
- Lecture: G. Zimet (US) 8:40 - 9:00
- Surveys: Consumer Knowledge of HPV / Cervical Cancer 9:00 - 9:20  
Including : - Awareness of HPV - Knowledge about screening options  
- Vaccine acceptability (role of mothers for girls) - Main sources of information  
- First experience from implementation of HPV vaccination
- 3 presenters: - J. Wardle (UK)  
- R. Haupt (US)  
- P. Rasmussen (US)

#### 1.2 HPV Vaccines & Testing: Communicating Sophisticated Science in Simple Messages **9:20 – 9:50**

Chair: C. Wheeler (US) - M. Pitts (Australia)

- Lecture: J. Wardle (UK) 9:20 - 9:35
- Round table 9:35 - 9:50  
J. Smith (US) - J. Waller (UK) - S. Garland (Australia) - S. Fehl (Germany) - M. Steben (Canada)  
- Health literacy  
- Psychological/behavioral barriers  
- Cultural differences

#### 1.3 The Role of Health Care Professionals **9:50 – 10:30**

Chair: D. Saslow (US) - H. Sancho-Garnier (France)

- Lecture: H. Sancho-Garnier (France) 9:50 - 10:10
- Round table 10:10 - 10:30  
- ACS (American Cancer Society): D. Saslow (US)  
- UICC (Int. Union against Cancer): H. Sancho-Garnier (France)  
- EFC (European Federation of Colposcopy): J. Jordan (UK)  
- ASCCP (American Society of Colposcopy and Cervical Pathology): T. Cox (US)  
- EUROGIN (European Research Organisation on Genital Infection and Neoplasia): A. Singer (UK)

**Coffee Break 10:30 – 11:00**

### SESSION 2

Camille Blanc auditorium

#### 2.1 Role of Governmental and Public Health Authorities **11:00 – 11:45**

Chair: L. Von Karsa (IARC - France) – J. Schiller (NCI - US)

- Lecture: L. Von Karsa (IARC - France) 11:00 - 11:20
- Round table 11:20 - 11:45  
- WHO (World Health Organization): K Irwin (Switzerland)  
- IARC: C. Sauvaget (France)  
- CDC (Center for Disease Control): H. Lawson (US)  
- NCI (National Cancer Institute): J. Schiller (US)  
- INSP (Institut National de Santé Publique du Québec): M. Steben (Canada)  
- INCa (Institut National du Cancer - France): E. Bara (France)

### SESSION 2 (continued)

Camille Blanc auditorium

#### 2.2 Role of Non-Governmental Organizations **11:45 – 13:00**

Chair: S. Crosby (US) – P. Morton (UK)

- Testimonial: A. Nightingale (UK) 11:45 - 11:55
- Lecture 1: S. Crosby (US- Women in Government) 11:55 - 12:10
- Lecture 2: I. Natividad (US- Global Summit of Women) 12:10 - 12:25
- Round table 12:25 - 13:00  
- Jo's Trust: P. Morton (UK)  
- ECCA - European Cervical Cancer Association: P. Davies (France)  
- ECL - Association of European Cancer Leagues: G. Agnarsdottir (Iceland)  
- EIWH - European Institute of Women's Health: P. Maguire (Ireland)  
- Balm in Gilead: P. Seele (US)  
- 1000 femmes pour 1000 vies – The French experience: MJ Deshaies (France)

### SESSION 3

Camille Blanc auditorium

#### 3.1 Role of Media (Including digital and Internet communications) **14:00 – 14:30**

Chair: P. Maguire (Ireland)

- Lecture: V. Parry (UK) 14:00 - 14:20
- Discussion 14:20 - 14:30

#### 3.2 Role of Pharmaceutical Companies and Industries **14:30 – 15:30**

Chair: P. Van Damme (Belgium)

- Lecture: P. Van Damme (Belgium) 14:30 - 14:50
- Round table: L. Alexander (US) - H. Bogaerts (Belgium) - L. Hessel (France) 14:50 - 15:30

**Coffee Break 15:30 – 16:00**

### SESSION 4

Camille Blanc auditorium

#### 4.1 Conclusions from the Round Table Discussions **16:00 – 17:15**

Chair: H. Lawson (US) - A. Singer (UK)

- Lessons Learned: Identifying the most effective communication tools.
- Summary presentation 16:00 - 16:20
  - Round table 16:20 - 17:15  
T. Cox (US) - C. Weil-Olivier (France) - C. Wheeler (US) - M. Pitts (UK)  
- H. Sancho-Garnier (France) - N. Berman (US) - L. Brabin (UK) - S. Crosby (US) - P. Morton (UK)  
- H. Lawson (US) - J. Smith (US) - MJ. Deshaies (France) - I. Natividad (US) - D. Saslow (US)

#### 4.2 Closing **17:15 – 17:30**

Chair: J. Wardle (UK) - MJ. Deshaies (France)

- Commitment to follow-up surveys on women's knowledge of HPV prior to each EUROGIN meeting
- Launch of the HPV education/advocacy collaboration  
- Objectives - Action steps  
- Building a European Educational Network



# Scientific Sessions

Friday, October 5

Salle des Princes auditorium

**SS 1 Vaccines 14:00 – 15:00**

*Chair: K. Ault (US) - P. Van Damme (Belgium)*

- SS1-1** • Estimating prior HPV-16/18 exposure by age group of women enrolled in phase III clinical trials of GSK's HPV vaccine R. Skinner (Australia)
- SS1-2** • Efficacy and safety of GSK's HPV vaccine in women initially seropositive or seronegative for HPV-16/18 in a phase III trial M. Cruickshank (UK)
- SS1-3** • Prophylactic efficacy of quadrivalent HPV types 6, 11, 16, 18 L1 virus-like particle vaccine against HPV types 6/11-related cervical, vulvar, and vaginal neoplasias and condyloma acuminata: 3 year follow-up analysis E. Joura (Austria)
- SS1-4** • Efficacy of a quadrivalent vaccine among European women – 3 years of follow-up S. Majewski (Poland)

**SS 2 Vaccines 15:00 – 16:00**

*Chair: L. Gissmann (Germany) - P. Coursaget (France)*

- SS 2-1** • Methodology for analysis of the efficacy of quadrivalent HPV vaccine against non vaccine types E. Barr (US)
- SS 2-2** • Quadrivalent human papillomavirus (HPV) type 6, 11, 16, 18 L1 virus like particle vaccine: an analysis of cross protection against cervical intraepithelial neoplasia caused by non-vaccine types L. Villa (Brazil)
- SS 2-3** • Immune response in women up to 55 years of age vaccinated with Cervarix™, the HPV-16/18 VLP AS04 vaccine candidate T. Schwarz (Germany)
- SS 2-4** • Safety of a human papillomavirus (HPV) 16/18 AS04 cervical cancer vaccine candidate in women aged 26 years or older A. Szarewski (UK)
- SS 2-5** • Upper respiratory delivery of HPV VLP vaccines J. Schiller (US)
- SS 2-6** • Heterologous prime-boost immunization protocols with a recombinant Semliki Forest virus vector and virosomes T. Daemen (Netherlands)

**Genevoix**

**SS 3 Epidemiology of HPV and Cancer: Outstanding Issues and Challenges ahead 14:00 – 15:00**

*Chair: X. Bosch (Spain) - J. Smith (US)*

- SS 3-1** • Understanding the HPV natural history: latency and persistency (describe accurately the concepts and ways to measure them in trials/projects) B. Moscicki (US)
- SS 3-2** • HPV type distribution in cervical cancer, the secular trend vision S. De Sanjosé (Spain)
- SS 3-3** • The role of cofactors for progression: update on hormonal factors, smoking and dietary factors J. Smith (US)
- SS 3-4** • Understanding type replacement and how to plan studies to detect it J. Dillner (Sweden)
- SS 3-5** • Phase IV projects in developed and developing countries: designs and time table PH. Mayaud (UK)

**Scientific Sessions**

Friday, October 5

Genevoix

**SS 4 Interactive Case Presentations – Test your Skills in Colposcopy 15:00 – 16:00**

*Chair: R. Jones (New Zealand) / S. Dexeus (Spain)*  
*Coordination: A. Ferenczy (Canada)*

- M. Roy (Canada)
- E. Diakomanolis (Greece)
- K.U. Petry (Germany)
- J.C. Boulanger (France)
- S. Tatti (Argentina)

**Van Dongen**

**SS 5 HPV Genotyping 14:00 – 15:00**


*Chair: A. Lorincz (US) / S. Franceschi (France)*

- SS 5-1** • Introduction on HPV types in women, by presence of cervical lesions and by HIV status from IARC studies S. Franceschi (US)
- SS 5-2** • Latest developments in HPV genotyping technology P. Snijders (Netherlands)
- SS 5-3** • HPV genotypes, variants and mutants update from the molecular epidemiology laboratory T. Iftner (Germany)
- SS 5-4** • Epidemiological issues related to HPV genotypes in different world populations G. Clifford (France)
- SS 5-5** • Clinical utility of HPV genotyping P. Castle (US)
- SS 5-6** • Q & A A. Lorincz (US)

**SS 6 HPV Screening 15:00 – 16:00**

*Chair: C. Meijer (Netherlands) / W. Kinney (US)*

- SS 6-1** • The European guidelines C. Meijer (Netherlands)
- SS 6-2** • US experience W. Kinney (US)
- SS 6-3** • Swedish trial J. Dillner (Sweden)
- SS 6-4** • Canadian cervical screening trial M.H. Mayrand (Canada)
- SS 6-5** • Italian Trial G. Ronco (Italy)
- SS 6-6** • Finnish Trial M. Hakama (Finland)
- SS 6-7** • Dutch experience C. Meijer (Netherlands)
- SS 6-8** • UK experience J. Cuzick (UK)



# Scientific Sessions

**Saturday, October 6**  
**Prince Pierre auditorium**

**SS 7** **Cytopathology, Genotyping and Molecular Markers** **14:30 - 16:00**

*Chair: K. Syrjänen (Finland) / M. v. Knebel-Doeberitz (Germany)*

- |               |  |                                  |
|---------------|--|----------------------------------|
| <b>SS 7-1</b> | • HPV DNA testing  | M. Stoler (US)                   |
| <b>SS 7-2</b> | • Strategies to identify molecular markers   | M. v. Knebel-Doeberitz (Germany) |
| <b>SS 7-3</b> | • Individual markers and panel of markers. Experience from a multivariate modelling in clinical setting                      | K. Syrjänen (Finland)            |
| <b>SS 7-4</b> | • Performance characteristics of the APTIMA HPV assay  | J. Dockter (US)                  |
| <b>SS 7-5</b> | • Application in cytological samples: diagnosis vs. screening setting  | J.P. Bogers (Belgium)            |
| <b>SS 7-6</b> | • Potential benefit of using the PreTect HPV Proofer assay for follow-up of the prophylactic vaccine against cervical cancer | F. Karlsen (Norway)              |
| <b>SS 7-7</b> | • HPV as a primary screening test: p16 <sup>ink4a</sup> expression in cervical specimens to triage HR-HPV positive           | F. Carozzi (Italy)               |
| <b>SS 7-8</b> | • Potential roles and clinical utility of p16 immuno-cytochemistry as a diagnostic adjunct in cervical pathology             | C. Bergeron (France)             |
| <b>SS 7-9</b> | • Biomarker testing in cervical cancer screening: preliminary results from a Canadian multicentre study                      | S. Ratnam (Canada)               |

**SS 8** **Developing Countries** **16:00 - 17:30**

*Chair: J. Smith (US) / R. Sankaranarayanan (France)*

- |               |  |                              |
|---------------|--|------------------------------|
| <b>SS 8-1</b> | • Cervical screening in sub-Saharan Africa   | T. Ngoma (Tanzania)          |
| <b>SS 8-2</b> | • Efficacy of treatment of CIN in field conditions in developing countries                         | O. Esmay (India)             |
| <b>SS 8-3</b> | • Effect of visual screening on cervical cancer incidence and mortality: randomised trial evidence | R. Sankaranarayanan (France) |
| <b>SS 8-4</b> | • Molecular testing of self-collected samples in patients with cervical cancer                     | G. Dreyer (South Africa)     |
| <b>SS 8-5</b> | • Development of new cervical screening tests for use in developing countries. START project       | C. Sauvaget (France)         |
| <b>SS 8-6</b> | • HPV vaccination in developing countries: the promise and the problems                            | J. Smith (US)                |

## Scientific Sessions

**Saturday, October 6**  
**Genevoix**

**SS 9** **Management** **14:30 - 16:00**

*Chair: A. Singer (UK) / T. Cox (US)*

- |               |  |                          |
|---------------|--|--------------------------|
| <b>SS 9-1</b> | • Who should be sent for colposcopy?                       | T. Cox (US)              |
| <b>SS 9-2</b> | • Basics for good colposcopy                               | J. Jordan (UK)           |
| <b>SS 9-3</b> | • How accurate is colposcopy?                              | S. Dexeus (Spain)        |
| <b>SS 9-4</b> | • Are local destructive methods for treatment still valid? | J.L. Mergui (France)     |
| <b>SS 9-5</b> | • New methods of management                                | W. Prendiville (Ireland) |
| <b>SS 9-6</b> | • Consequences and follow-up after treatment               | A. Singer (UK)           |

**SS 10** **Immunology** **16:00 - 17:30**

*Chair: J. Dillner (Sweden) / S. Pagliusi (Switzerland)*

- |                |   |                                      |
|----------------|---|--------------------------------------|
| <b>SS 10-1</b> | • Innate and adaptative immune responses to HPV   | B. Moscicki (US)                     |
| <b>SS 10-2</b> | • Immunological aspects of mucosal vaccination    | D. Nardelli-Haeffliger (Switzerland) |
| <b>SS 10-3</b> | • Assembly of a WHO global HPV laboratory network | J. Dillner (Sweden)                  |
| <b>SS 10-4</b> | • Applications of multiplex HPV serology          | M. Pawlita (Germany)                 |

## Poulenc

**SS 11** **HPV Infection in Non Cervical Sites** **14:30 - 16:00**

*Chair: J. Bornstein (Israel) / J. Palefsky (US)*

- |                |  |                        |
|----------------|--|------------------------|
| <b>SS 11-1</b> | • Role of immunization   | S. Syrjänen (Finland)  |
| <b>SS 11-2</b> | • Vulva and HPV  | R. Jones (New Zealand) |
| <b>SS 11-3</b> | • Genital warts: overview of current knowledge and future directions | A. Ferenczy (Canada)   |
| <b>SS 11-4</b> | • Recurrent Respiratory Papillomatosis                               | T. Broker (US)         |
| <b>SS 11-5</b> | • Oral, sinonasal, oesophageal, bronchial, ocular HPV                | S. Syrjänen (Finland)  |
| <b>SS 11-6</b> | • HPV in homosexual men  | J. Palefsky (US)       |

**SS 12** **Epidemiology** **16:00 - 17:30**

*Chair: E. Franco (Canada) / S. Syrjänen (Finland)*

- |                |  |                       |
|----------------|--|-----------------------|
| <b>SS 12-1</b> | • Epidemiology of HPV infection and cervical cancer  | E. Franco (Canada)    |
| <b>SS 12-2</b> | • Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis  | J. Smith (US)         |
| <b>SS 12-3</b> | • HPV in males   | J. Smith (US)         |
| <b>SS 12-4</b> | • HPV types detected in biopsy tissue collected from the surface of an invasive cervical tumor may not represent the HPV type involved in the carcinogenesis | E. Willander (Sweden) |
| <b>SS 12-5</b> | • Type-specific acquisition, persistence and clearance (NIS cohort study)  | S. Syrjänen (Finland) |
| <b>SS 12-6</b> | • HIV and HPV lessons from the HIV cohorts   | J. Palefsky (US)      |

**FC 1** **Epidemiology and Natural History** **8:30 - 9:30**

*Chair: J. Smith (US) / C. Mouglin (France)*

- FC 1-1** • Duration of type-specific HPV infection : implications for HPV screening and vaccination  
H. Trottier (Canada)
- FC 1-2** • Burden of genital warts in Spain  
V. Rémy (France)
- FC 1-3** • Clinical follow-up of women infected with HPV16 either alone or with other HPV types: identification of different groups  
S. Gerber (Switzerland)
- FC 1-4** • Interaction between different STIs in the aetiology of cervical cancer  
K. Andersson (Sweden)
- FC 1-5** • Invasive cervical cancer in the United States: variations in histology by race/ethnicity  
M. Watson (US)
- FC 1-6** • Serological and molecular evidence of HPV 16 being the predominant type etiologically involved in penile squamous cell carcinoma  
D. Heideman (Netherlands)
- FC 1-7** • How to screen asymptomatic men for HPV  
W. Tjalma (Belgium)
- FC 1-8** • HPV concordance among couples who recently initiated a sexual relationship: results from the HITCH cohort study  
E. Franco (Canada)

**FC 2** **Screening of Cervical Cancer** **9:30 - 10:45**

*Chair: K.U. Petry (Germany) / J.C. Boulanger (France)*

- FC 2-1** • HPV adjunct testing in the United States: minimal impact on screening intervals  
K. Roland (US)
- FC 2-2** • VUSA-Screen: a population-based cervical screening trial in The Netherlands comparing HC2 and conventional cytology with cytology  
D. Rijkaart (Netherlands)
- FC 2-3** • Risk of cervical cancer in women with a history of three or more negative smears around age 50  
M. Rebolj (Netherlands)
- FC 2-4** • Cytological history of cervical invasive cancer. Results of a 2006 French survey  
J.C. Boulanger (France)
- FC 2-5** • A randomised controlled trial of HPV testing for cervical cancer screening: HPV focal study  
D. Van Niekerk (Netherlands)
- FC 2-6** • 18 months experiences: primary HPV screening project in Wolfsburg, Germany  
K.U. Petry (Germany)
- FC 2-7** • Prospective cohort study of HPV testing combined with conventional cytology in cervical cancer screening in Japan  
R. Konno (Japan)
- FC 2-8** • Coverage or quality? Auditing the performance of a national cervical screening programme  
H. Lewis (New Zealand)

**FC 3** **HPV Prophylactic Vaccines** **11:00 - 13:15**

*Chair: J. Dillner (Sweden) / S. Garland (Australia)*

- FC 3-1** • Immunotherapy for HPV infection - Lessons from an animal model  
I. Frazer (Australia)
- FC 3-2** • Quadrivalent HPV types 6/11/16/18 L1 virus-like particle vaccine in preventing cervical intraepithelial neoplasia (CIN): 3-year efficacy  
S.E. Olsson (Sweden)
- FC 3-3** • Efficacy of a quadrivalent HPV types 6/11/16/18 L1 virus-like particle (VLP) vaccine against vulvar and vaginal intraepithelial neoplasia  
J. Paavonen (Finland)
- FC 3-4** • Efficacy of quadrivalent HPV vaccination against condylomata and low-grade cervical, vulvar, and vaginal intraneoplasias  
J. Dillner (Sweden)
- FC 3-5** • The quadrivalent HPV (types 6/11/16/18) vaccine: experience from Latin American women  
G. Perez (Colombia)
- FC 3-6** • The potential impact of the HPV vaccine on Pap tests and procedures: ambulatory care visits in the United States, 2003-05  
M. Saraiya (US)
- FC 3-7** • Clinical benefits of a cervical cancer vaccine candidate among multiple us female cohorts based on a mathematical model  
D. Taylor (US)
- FC 3-8** • Long term clinical effect of prophylactic vaccination against cervical cancer in Parana, Brazil: results from a Markov model  
N. Sergio de Carvalho (Brazil)
- FC 3-9** • Economic assessment of prophylactic cervical cancer vaccination: discounting methods for health effects debated  
B. Standaert (Belgium)
- FC 3-10** • Assessment of the health and economic impact of a quadrivalent HPV vaccine in the United Kingdom using a transmission dynamic model  
E. Dasbach (US)
- FC 3-11** • Cost-effectiveness of a cervical cancer vaccine candidate in 12-year-old females in the US based on a health economic model  
D. Kruzikas (US)
- FC 3-12** • Modelling cost-effectiveness of cervical cancer vaccination in countries with different screening practices  
R. Rogoza (Canada)
- FC 3-13** • A multi-country analysis comparing two HPV vaccines against cervical cancer: results from a health economic model  
J. Tamminga (Netherlands)
- FC 3-14** • Vaccination and follow-up to prevent HPV infection and cervical cancer: adolescents vs. women  
F. Borruto (Italy)
- FC 3-15** • Anti-HPV capsid antibodies in sexual workers and controls in the Czech Republic  
E. Hamsikova (Czech Republic)
- FC 3-16** • Transcutaneous DNA immunization of HPV-16 E7 with hair follicle specific promoter in mice  
C.J. Kim (South Korea)
- FC 3-17** • Potential factors influencing the response to Transgene's therapeutic vaccine TG4001 in HPV 16 CIN 2/3 women.  
J.L. Brun (France)
- FC 3-18** • A polyepitope approach to HPV therapeutic vaccination  
H. De Winter (Belgium)

**FC 4** **Societal Issues of HPV Infection and Immunization** **14:00 - 16:00**

*Chair: M. Pitts (Australia) / J. Waller (UK)*

- FC 4-1** • What do women need to know about HPV as a "test of cure" following cervical dysplasia?  
M. Pitts (Australia)
- FC 4-2** • Attitudes to HPV vaccination in British Women (16-64 years) - a population representative sample  
J. Wardle (UK)
- FC 4-3** • Trust and experience as predictors of HPV vaccine acceptance  
J. Waller (UK)
- FC 4-4** • Canadian obstetricians-gynaecologists' opinions regarding HPV vaccines and cervical cancer screening  
M. Steben (Canada)
- FC 4-5** • Knowledge about and attitudes to Pap smears, cervical cancer and HPV among women in Slovenia  
M. Ursic Vrscaj (Slovenia)

- FC 4-6** • Attitudes to HPV vaccination among parents to children aged 12-15 years – a population based survey in Sweden  
P. Sparen (Sweden)
- FC 4-7** • Does giving HPV information modify perceived risk of cervical cancer?  
L. Marlow (UK)
- FC 4-8** • How gynaecologists can become human papillomavirus (HPV) immunizers: Québec's experience?  
M. Fortier (Canada)
- FC 4-9** • A hospital-based study of the knowledge and attitude of mothers of adolescents regarding HPV infection and its potential vaccine  
C. Zalameda-Castro (Philippines)
- FC 4-10** • Issues for mass immunisation of HPV vaccine in mixed culture communities  
M. Heffernan (Australia)
- FC 4-11** • Potential impact of HPV quadrivalent vaccine on the different cohort of young women  
A. Biamonti (Italy)

**FC 5** **Viral and Molecular Biology** **16:00 - 17:15**

*Chair: S. Syrjänen (Finland) / J.L. Prétet (France)*

- FC 5-1** • Complete recapitulation of the HPV-18 infection cycle in organotypic cultures of primary human keratinocytes  
T. Broker (US)
- FC 5-2** • The use of human papillomavirus promoter to target cervical cancer cells  
M.S.Y. Lung (Australia)
- FC 5-3** • HPV16 physical status study: integration percentage, viral load, E2 and E6 expression, how to link them?  
M. Saunier (France)
- FC 5-4** • Oral administration of high molecular weight g-PGA (2,000 kDa) generated significant NK cell-mediated anti-tumor activity in mice bearing MHC class I-deficient tumor expressing HPV16 E6 and E7  
M.H. Sung (South Korea)
- FC 5-5** • Intracellular zinc accumulation inhibits expression of HPV E6/E7 genes by targeting selective transcriptional factors in the URR  
S. Bae (South Korea)
- FC 5-6** • Methylation of tumor suppressor genes PI6INKA4 and RASSF1A is rare event in HPV-positive cervical squamous cell carcinomas  
N. Kisseljova (Russia)
- FC 5-7** • Functional analysis of CDC7 protein which is interacted with HPV E6  
Y.S. Lee (South Korea)
- FC 5-8** • Why do HPV-infections induce sharply demarcated lesions of the cervix?  
O. Reich (Austria)

**FC 6** **Management** **17:15 - 18:40**

*Chair: M. Roy (Canada) / A. Perino (Italy)*

- FC 6-1** • A new optical imaging system for the in vivo detection, grading and biopsy sample guiding of cervical neoplasia  
C. Balas (Greece)
- FC 6-2** • Dynamic spectral imaging – in vivo detection and quantitative grading of cervical neoplasia  
W.P. Soutter (UK)
- FC 6-3** • A quantitative non destructive characterisation integrated system for pattern recognition applied in early diagnosis of cervix cancer  
D. Pereira da Silva (Portugal)
- FC 6-4** • Colposcopic management of AGC  
M. Jacot-Guillarmod (Switzerland)
- FC 6-5** • Pregnancy outcome after conisation: a retrospective cohort study  
A. Van de Vijver (Belgium)
- FC 6-6** • Detection and typing of "high-risk" HPV as treatment control after conization  
S. Brismar (Sweden)
- FC 6-7** • Developing optimum follow-up strategies after treatment of CIN: a C-5 group follow-up scoring system (FUSS)  
P. Martin-Hirsch (UK)
- FC 6-8** • Cancer free survival after CIN treatment: comparisons of treatment methods and histology  
I. Kalliala (Finland)
- FC 6-9** • Stage IA cervical carcinoma: disease outcome of 566 cases  
S. Smrkolj (Slovenia)
- FC 6-10** • Radiofrequency treatment of vaginal intraepithelial neoplasia: our experience  
G. Perrini (Italy)

**FC 7** **HPV Testing** **8:00 - 10:00**

*Chair: P. Snijders (Netherlands) / C. Clavel (France)*

- FC 7-1** • Performance characteristics of Amplicor® HPV PCR and Linear Array genotyping on SurePath® Pap samples  
M. Chernesky (Canada)
- FC 7-2** • Comparison of Hybrid Capture 2 (HC2) and Amplicor HPV (MWP HPV) tests for the triage to colposcopy of women with ASCUS  
F. Coutlée (Canada)
- FC 7-3** • Performance of the Roche Amplicor® human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal Pap smear  
J. Monsonogo (France)  
K. Syrjänen (Finland)
- FC 7-4** • Reflex HPV testing of ASCUS Pap samples in postmenopausal women  
A.K. Goodman (US)
- FC 7-5** • Papillomavirus (HPV) DNA load in urine and cervical samples using quantitative HPV DNA real-time PCR and HC II assays  
C. Payan (France)
- FC 7-6** • Performance of urinary HPV detection by PCR for high grade cervical lesions.  
J.C. Boulanger (France)
- FC 7-7** • PCR amplification of DNA from archival Papanicolaou-stained cervical smears  
C. Horvath (Belgium)
- FC 7-8** • Improved identification of CIN 2-3 using cytology combined with a high-risk HPV test in the secondary screening  
B. Andrae (Sweden)
- FC 7-9** • High risk HPV DNA in-situ hybridization test and follow-up results on ASC-H cases in routine clinical practice  
T. Giordadze (US)
- FC 7-10** • The feasibility of HPV in situ hybridisation to predict the outcome of CIN1  
J. Hariri (Denmark)
- FC 7-11** • Prevention by offering hrHPV testing on self-sampled cervicovaginal specimens trial (PROTECT) – interim findings  
F. Van Kemenade (Netherlands)
- FC 7-12** • The value of viral load assessment in the triage of hrHPV positive women to detect CIN2+: a cohort study  
P. Snijders (Netherlands)
- FC 7-13** • Cost-effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa  
A. Vijayaraghavan (South Africa)

**FC 8 Molecular Markers****13:15 - 15:00**

Chair: M. Stoler (US) / C. Bergeron (France)

- FC 8-1** • p16 ELISA based detection of HGCIN using non-directed and directed sampling  
N. Wentzensen (Germany)
- FC 8-2** • Determination of p16<sup>ink4a</sup> expression in cervical intraepithelial neoplasia grade 2 and 3 lesions diagnosed in a population-based screening setting  
C. Meijer (Netherlands)
- FC 8-3** • Utility of p16<sup>ink4a</sup> as an adjuvant diagnostic tool in interpretation of ASC-H and AGC: a prospective study of 532 patients  
M. Chivukula (US)
- FC 8-4** • Cervical biopsy: is the histological diagnosis reliable and reproducible? The utility of p16<sup>ink4a</sup> in its achievement  
J.J. Curiel-Valdes (Mexico)
- FC 8-5** • Correlation of p16 immunostaining to cervical intraepithelial neoplasia and high-risk human papillomavirus infection  
I. Tsoumpou (UK)
- FC 8-6** • p16<sup>ink4a</sup> immunocytochemistry in liquid-based cytology (LBC) samples gives added value in management of women with equivocal Pap smear  
J. Monsonego (France)  
K. Syrjänen (Finland)
- FC 8-7** • Comparison of HPV detection technologies, Hybrid Capture 2 (Digene), Pretest HPV Proofer (Norchip) and real time PCR for detection of HPV in cervical cytology specimens.  
H. Keegan (Ireland/Norway)
- FC 8-8** • HPV mRNA detection in different stages of cervical adenocarcinomas  
S. Hovland (Sweden)
- FC 8-9** • HPV E6/E7 DNA and RNA detection in SurePath liquid based cytology for improved prediction of CIN2+  
C. Depuydt (Belgium)
- FC 8-10** • High-risk HPV E7 oncoprotein detection in cervical cancer  
K. Dreier (Austria)
- FC 8-11** • Use of the SurePath™ transport media and its effect on mRNA amplification by the NASBA based Pretest HPV-Proofer® diagnostic assay  
I. Silva (Norway)
- FC 8-12** • Biomarkers and their predictive value in cervical carcinogenesis  
M. Ciotti (Italy)
- FC 8-13** • Chromosomal alterations assessed by fish in HPV infected cervical epithelial cells  
I. Sokolova (US)

**FC 9 Genotyping****15:00 - 16:30**

Chair: P. Castle (US) / T. Iftner (Germany)

- FC 9-1** • HPV16 viral load, integration, coinfections, ploidy and progression of cervical lesions  
C. Clavel (France)
- FC 9-2** • A comparison of Linear Array and line blot assay for detection of HPV and cervical precancer and cancer in ALTS  
P. Castle (US)
- FC 9-3** • High throughput genotyping of oncogenic human papillomaviruses using Maldi-Tof mass spectrometry  
A. Soderlund-Strand (Sweden)
- FC 9-4** • Linear Array HPV genotyping as a triage test in primary gynaecological screening  
M. Fröberg (Sweden)
- FC 9-5** • Detection of human papillomavirus (HPV) genotypes among high-risk women: a comparison of Hybrid Capture and Linear Array tests  
J. Monsonego (France)  
K. Syrjänen (Finland)
- FC 9-6** • A comparative analysis of HPV detection systems: MY09/11 consensus PCR versus type-specific PCRS  
G. Boulet (Belgium)
- FC 9-7** • Single and multiple HPV infections associated with cervical abnormalities by using clinical array HPV assay  
A. Pista (Portugal)
- FC 9-8** • Human papillomavirus (HPV) genotype distribution in low-grade cervical lesions in France: the EDITH III study  
A.C. Jacquard (France)
- FC 9-9** • Human papillomavirus genotypes in low-grade cervical lesions. Comparison with cervical cancer: the EDITH study  
J.L. Prétet (France)

**CH Cyto-histology**

- CH01** • Glandular cell abnormalities in cervical smears according to the Bethesda 2001 classification: cytohistological correlation  
ZEFERINO (Brazil)
- CH02** • How useful is the existent cervical mucous, comparison with a second sample.  
J.J. CURIEL-VALDES (Mexico)
- CH03** • Simultaneous screening with liquid based cytology and PCR HPV genotyping in a sample of 1067 Italian women  
E. CASOLATI (Italy)
- CH04** • Liquid based cytology in molecular research: viability and potential applications  
A. LONGATTO-FILHO (Portugal)
- CH05** • Prevalence of CIN 2-3 in patients with cytological diagnosis of ASC-H and ASC-US.  
F. RUSSOMANO (Brazil)

**EP Epidemiology**

- EP01** • High risk human papillomavirus cervical infections associated with increasing high-grade squamous intraepithelial lesion  
N. CERNEA (Romania)
- EP02** • Human papilloma virus prevalence in cases of cervical lesions  
F.L. CORNITESCU (Romania)
- EP03** • Prevalence of cervical human papillomavirus in Azorean women  
I. DUTRA (Portugal)
- EP04** • Changes in the number and characteristics of patients with vulvar carcinoma in a German university hospital over 30 years  
M. HAMPL (Germany)
- EP05** • HPV type-specific prevalence and related factors in Korean women  
C.J. KIM (South Korea)
- EP06** • Prevalence of cervical infection by human papillomavirus after renal transplant  
C. MARQUES (Portugal)
- EP07** • Prevalence of human papillomavirus (HPV) genotypes in a routine cervical sample material from Norway  
H.M. SKAUG (Norway)

**GT Genotyping**

- GT01** • HPV52 viral load and integration in cervical neoplasia  
P. CHAN (China)
- GT02** • Preliminary studies about HPV most frequent genotypes for the next strategy of HPV vaccinations in Romania  
N. COMAN (Romania)
- GT03** • Genotyping for eight oncogenic types of human papillomavirus can improve specificity of HPV testing in women with mild abnormal Pap results  
M. GUO (Taiwan)
- GT04** • Genotyping of human papillomavirus in triage cell samples by a nested, multiplex PCR (NMPCR)  
B. HAGMAR (Norway)
- GT05** • Detection and typing human papillomavirus using nested polymerase chain reaction and reverse line blot hybridization  
T.K.L. HOANG (Australia)
- GT06** • Persistence of human papillomavirus as a predictor for treatment failure after LEEP  
S.J. LEE (South Korea)
- GT07** • Molecular characterization of HPV16 viral infection  
L. MARTINS (Portugal)
- GT08** • Cytological correlations of the cervical lesions detected with low-/high-risk HPV genotypes  
N. MOCIULSCHI (Romania)
- GT09** • High risk HPV frequencies in Portugal: comparison between genotyping and Hybrid Capture  
D. PINTO (Portugal)

**HT HPV Testing**

HT01	• A prototype real-time PCR test for detection of high risk HPV DNA in liquid based cytology samples	K. ABRAVAYA (USA)
HT02	• Development of a NucliSENS EasyQ human papillomavirus assay	E. JACOBS (Netherlands)
HT03	• EHEQAS: European HPV DNA test external quality assurance scheme	P. NEOPHYTOU (Greece)
HT04	• Self collected HPV testing identifies women at risk for positive cytology and CIN2+ lesions	N. SPOLTI (Italy)
HT05	• Comparison of the flocced SWAB+UTM to the CYTOBRUSH+PBS for collection of cervical specimens for molecular detection of human papilloma virus DNA	A. VERRI (Italy)
HT06	• Comparison of an in-house HPV-DNA PCR test with 2 commercially HPV-DNA tests	M. WALDSTROM (Denmark)
HT07	• Evaluation of (pre-) commercial HPV-genotyping assays on HC2 positive samples from a normal screening population	E. WENTZENSEN (Germany)
HT08	• Self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening	I. WIKSTROM (Sweden)
HT09	• Evaluation of the PapilloCheck HPV test by a threewise comparison of genotyping tests applied to 881 cervical smears pre-screened by HC2	T. IFTNER (Germany)
HT10	• Vaginal sampling with flocced swabs detected more HPV infections than rayon swabs and cervical sampling	S. CASTRICIANO (Italy)
HT11	• Estimating the Number of Cytologic Specimens Required in a Cervical Screening Program in Australia Utilising Primary HPV Testing and Reflex Cytologic Examination of HR HPV Positive Women	J. GRACE (Australia)
HT12	• HPV prevalence in cytologically normal cervical smears	E. PANOTOPOULOU (Greece)

**MT Management**

MT01	• HPV status in sentinel nodes might be a prognostic factor in cervical cancer	J.S. PARK (South Korea)
MT02	• Conization of cervical intraepithelial neoplasia using the Harmonic Scalpel	H. YAMAKAWA (Japan)
MT03	• Colposcopic evaluation and follow-up of a vulvar intraepithelial neoplasia (VIN)	M. KEMPF HABER (Switzerland)
MT04	• Conization using loop electrosurgical excision procedure and cold coagulation for FIGO stage IA1 cervical carcinoma	B.G. KIM (South Korea)
MT05	• Utilization of human papillomavirus genotype testing as a predictor of residual/recurrent disease in patients treated for high-grade CIN	Y.S. SONG (South Korea)
MT06	• Association of bacterial vaginosis with cervical intraepithelial neoplasia	Y.T. KIM (South Korea)
MT07	• A review of vulvar intraepithelial neoplasia in 9063 vulvoscopies	P. LUCA (Brazil)
MT08	• Clinical significance of high risk HPV test for the diagnostics of cervical intraepithelial neoplasia (CIN)	R. NADISAUSKIENE (Lithuania)
MT09	• Analyze of anal intraepithelial lesion associated factors relating to the positive gynecological sites in women with genital intraepithelial lesion	C. JACYNTHO (Brazil)

**MM Molecular Markers**

MM01	• Affect of different transport media on the amplification of mRNA using the HPV PreTect-Proofer diagnostic test	P. GRONN (Norway)
MM02	• Routine HPV diagnosis in clinical practice using an mRNA assay	F. KARLSEN (Norway)
MM03	• Altered expression of monocarboxylate transporters in pre-invasive and invasive lesions of the uterine cervix	A. LONGATTO-FILHO (Portugal)
MM04	• Statistical assessment of data generated by diagnostic methods for detection of a rare disease	E. MORLAND (Norway)
MM05	• Comparison of HPV detection by Hybrid Capture II test, PreTect HPV-Proofer Kit and Full Spectrum hpv amplification and detection system	A. SEBE (Hungary)
MM06	• Interferon- $\gamma$ receptor -56C>T polymorphism is a predictive biomarker for cervical cancer development in Portugal	H. SOUSA (Portugal)
MM07	• Every second positive preTect HPV-Proofer result have underlying CIN2+. Experience with reflex testing in Copenhagen	B.M. WIEBE (Denmark)

**SC Screening**

SC01	• Epidemiological evaluation of the four French districts organizing a cervical cancer screening	N. DUPOUR (France)
SC02	• HPV Prevalence and critical analysis of PAP smear for primary screening for cervical cancer during pregnancy after 30 years old. Intermediate analysis on 333 cases	E. VAUCEL (France)

**SI Societal Issues**

SI01	• Attitude survey on cervical cancer screening and HPV vaccine in Japanese women	T. OOMARU (Japan)
SI02	• Informed consent to vaccination against human papillomavirus (HPV). A bioethical proposal	L. SOMOGYI (Venezuela)

**VC Vaccines**

VC01	• Purpose of a score evaluation for demonstrating the efficacy of HPV quadrivalent vaccine	A. BIAMONTI (Italy)
VC02	• Human Papillomavirus type 16 virus like particles expressed in lactobacillus induce mucosal and systemic neutralizing antibodies in mice	H. POO (South Korea)

**VM Viral and Molecular Biology**

VM01	• Expression of proangiogenic factors VEGF, (VEGF)-C and their receptor VEGF-R2 in cervical intraepithelial neoplasia CIN and cervical cancer among non-pregnant and pregnant women	R. JACH (Poland)
VM02	• The hTERT expression in neoplastic cervical disease	A. SOCOLOV (Romania)